As previous studies reported, CDKN2A-mediated molecular subtypes identified drug sensitivity differences in afatinib, erlotinib, and lapatinib, and the higher expression of CDKN2A implied worse outcomes and molecular subtypes in breast cancer. The gene discussed is CDKN2A; the disease is breast cancer.